Lead Plaintiff Deadline: April 03, 2023
Please Upload related files below
Fill in below.
Looking for more?
(a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
In order to be included in the lawsuit, you must have incurred a loss on shares of Invivyd, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Invivyd, if applicable.
If you suffered a loss in Invivyd during the relevant time frame, or pursuant to Invivyd’s IPO if listed above, you have until April 03, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.